Passage of HR 3 is shaping up as a centerpiece of President Biden's effort to bring pharmaceutical prices under control. If drug companies won't negotiate prices, international reference pricing would kick in.
After issuing a number of directives in July targeted at lowering the cost of prescription drugs and getting biosimilars into play, President Biden has clarified his intentions with a request for Congress to take action on specific measures.
The request endorses passage of the Elijah E. Cummings Lower Drug Costs Now Act, which would enable HHS to negotiate prescription drug prices for Medicare beneficiaries and, if companies refuse to negotiate, would limit drug prices to 120% of average prices in Australia, Canada, France, Germany, and the United Kingdom.
The request also refers to an investigative report from the House Committee on Oversight and Reform that noted steep price increases for the rheumatology drug adalimumab (Humira) and contended these were excessive and unjustifiable.
In a July executive order, Biden directed the FDA to set up a means by which lower-cost pharmaceuticals could be imported from Canada. It directed HHS to increase support for generic and biosimilar drugs and asked HHS to develop a comprehensive plan for combating high prescription drug prices and price gouging. It also called upon the Federal Trade Commission to ban so-called pay-for-delay tactics that originator companies use to forestall competition for their most lucrative products.
Under the timeline Biden gave HHS to submit a plan for lowering drug costs, the report would be due in about 10 days, or August 23.
“For every other type of health care service, Medicare works to get the best prices for American seniors. But for prescription drugs–and only prescription drugs–Medicare is prohibited by law from negotiating for the best deal. This needs to change,” the Biden letter to Congress states.
Biden also calls for caps on out-of-pocket costs for Medicare beneficiaries and recommends a penalty for drug companies “that raise their prices faster than inflation.”
The Cummings bill, HR 3, was first introduced in 2019 and reintroduced in April 2021. It would allow HHS to negotiate with pharmaceutical companies over the prices of high-cost drugs for which there is no generic or biosimilar competition. HHS would start in 2024 by negotiating prices for 25 of the drugs with the highest spend and at least 50 more drugs “in following years.” These negotiations would include insulin products.
“If pharmaceutical companies refuse to negotiate, they would face civil and tax penalties,” according to the Center for American Progress (CAP), a liberal research and advocacy group cited by Biden in his message to Congress.
According to CAP, US drug prices are on average 2.56 times those in 32 peer counties. Under HR 3, if international prices cannot be obtained for drugs HHS wishes to negotiate, the agency would be permitted to set the price at 85% of the average manufacturer price.
The Congressional Budget Office estimates that savings from HR 3 would amount to almost $500 billion over a decade, according to CAP. Specifically, the cost for a 30-day supply of adalimumab and etanercept would be reduced by $2161 and $2086, respectively.
CAP said HR 3 would cap out of pocket drug costs for Medicare beneficiaries at $2000, down from the current $6550 out-of-pocket limit before catastrophic coverage kicks in under Medicare Part D.
The Biden letter to Congress was applauded by the Biosimilars Forum, a group of biosimilar manufacturers. We urge Congress to pass meaningful legislation that gives more patients access to lifesaving, lower-cost biosimilar therapies so we can realize the Affordable Care Act’s full potential to lowering drug costs,” said Meaghan R. Smith, executive director of the Biosimilars Forum.
For a legal perspective on Biden's pharmaceutical pricing initiatives, click here.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.